Published in Proteomics on September 01, 2009
Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 4.33
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem (2010) 1.52
Glycoproteomic analysis of antibodies. Mol Cell Proteomics (2013) 1.19
Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One (2012) 1.16
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11
Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J (2011) 1.08
Analytical and Functional Aspects of Antibody Sialylation. J Clin Immunol (2010) 1.07
Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One (2011) 1.07
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A (2015) 1.03
Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics (2014) 0.99
Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One (2013) 0.94
Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconj J (2012) 0.91
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs (2013) 0.91
Harnessing glycomics technologies: integrating structure with function for glycan characterization. Electrophoresis (2012) 0.89
Anti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) gene. J Biol Chem (2012) 0.88
Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol (2013) 0.87
Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients. World J Gastroenterol (2013) 0.86
Characterization of the human submandibular/sublingual saliva glycoproteome using lectin affinity chromatography coupled to multidimensional protein identification technology. J Proteome Res (2011) 0.84
Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology (2013) 0.84
Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies. BMC Immunol (2012) 0.82
Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation. MBio (2014) 0.79
Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute. Clin Exp Med (2013) 0.76
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies. Biochim Biophys Acta (2016) 0.76
Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation. Clin Exp Immunol (2014) 0.76
Increased Avidity of the Sambucus nigra Lectin-Reactive Antibodies to the Thomsen-Friedenreich Antigen as a Potential Biomarker for Gastric Cancer. Dis Markers (2015) 0.76
Fractionation of Fab glycosylated immunoglobulin G with concanavalin A chromatography unveils new structural properties of the molecule. Oncotarget (2016) 0.75
At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody. Sci Rep (2016) 0.75
Sialylated immunoglobulin G can neutralize influenza virus infection through receptor mimicry. Oncotarget (2016) 0.75
Anti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment. PLoS One (2015) 0.75
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J (2008) 2.49
Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (2011) 2.49
Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics (2008) 2.26
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
Class I alpha-mannosidases are required for N-glycan processing and root development in Arabidopsis thaliana. Plant Cell (2009) 1.83
Nucleotide and nucleotide sugar analysis by liquid chromatography-electrospray ionization-mass spectrometry on surface-conditioned porous graphitic carbon. Anal Chem (2010) 1.71
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis (2013) 1.64
Genome, secretome and glucose transport highlight unique features of the protein production host Pichia pastoris. Microb Cell Fact (2009) 1.63
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58
Engineering of Pichia pastoris for improved production of antibody fragments. Biotechnol Bioeng (2006) 1.58
Mass + retention time = structure: a strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans. Anal Chem (2007) 1.54
The effect of temperature on the proteome of recombinant Pichia pastoris. J Proteome Res (2009) 1.53
In planta protein sialylation through overexpression of the respective mammalian pathway. J Biol Chem (2010) 1.52
Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling. Brain (2009) 1.49
Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J Biol Chem (2009) 1.49
Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol (2003) 1.45
Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS (2007) 1.44
Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol (2004) 1.43
A unique beta1,3-galactosyltransferase is indispensable for the biosynthesis of N-glycans containing Lewis a structures in Arabidopsis thaliana. Plant Cell (2007) 1.40
Determination of site-specific glycan heterogeneity on glycoproteins. Nat Protoc (2012) 1.38
Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol (2010) 1.36
Molecular basis of N-acetylglucosaminyltransferase I deficiency in Arabidopsis thaliana plants lacking complex N-glycans. Biochem J (2005) 1.36
Production of a monoclonal antibody in plants with a humanized N-glycosylation pattern. Plant Biotechnol J (2007) 1.34
Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol (2006) 1.32
Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses (2006) 1.30
The Drosophila fused lobes gene encodes an N-acetylglucosaminidase involved in N-glycan processing. J Biol Chem (2005) 1.30
Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol Chem (2012) 1.25
Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol (2010) 1.24
Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol (2009) 1.22
Unexpected deposition patterns of recombinant proteins in post-endoplasmic reticulum compartments of wheat endosperm. Plant Physiol (2004) 1.22
Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol (2007) 1.20
Enzymatic properties and subcellular localization of Arabidopsis beta-N-acetylhexosaminidases. Plant Physiol (2007) 1.20
Influence of electrosorption, solvent, temperature, and ion polarity on the performance of LC-ESI-MS using graphitic carbon for acidic oligosaccharides. Anal Chem (2008) 1.19
In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J (2007) 1.19
Protein tyrosine O-glycosylation--a rather unexplored prokaryotic glycosylation system. Glycobiology (2010) 1.18
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS (2002) 1.17
Down-regulation of UDP-glucuronic acid biosynthesis leads to swollen plant cell walls and severe developmental defects associated with changes in pectic polysaccharides. J Biol Chem (2011) 1.16
Sulfoquinovose synthase - an important enzyme in the N-glycosylation pathway of Sulfolobus acidocaldarius. Mol Microbiol (2011) 1.15
A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS One (2010) 1.15
Dissecting individual steps of nitrogen transcription factor cooperation in the Aspergillus nidulans nitrate cluster. Mol Microbiol (2008) 1.15
Characterization and scope of S-layer protein O-glycosylation in Tannerella forsythia. J Biol Chem (2011) 1.14
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis (2011) 1.13
Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett (2006) 1.13
Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J (2007) 1.13
Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds. Proc Natl Acad Sci U S A (2007) 1.12
Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12. Mol Immunol (2004) 1.11
N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans. Glycobiology (2011) 1.10
HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS (2005) 1.08
Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol (2005) 1.08
Targeted knockouts of Physcomitrella lacking plant-specific immunogenic N-glycans. Plant Biotechnol J (2004) 1.08
The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J Virol (2008) 1.08
Comprehensive glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms. Proteomics (2006) 1.07
Construction of a functional CMP-sialic acid biosynthesis pathway in Arabidopsis. Plant Physiol (2008) 1.07
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity. PLoS One (2011) 1.07
Analytical and Functional Aspects of Antibody Sialylation. J Clin Immunol (2010) 1.07
Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol Bioeng (2006) 1.07
A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis (2011) 1.06
Activated protein C: more effective than nonactivated protein C? Crit Care Med (2003) 1.06
Sialic acid concentrations in plants are in the range of inadvertent contamination. Planta (2006) 1.06
Affinity of IgE and IgG against cross-reactive carbohydrate determinants on plant and insect glycoproteins. J Allergy Clin Immunol (2007) 1.06
Glycan analysis by modern instrumental methods. Proteomics (2011) 1.06
Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics (2008) 1.06
Expression and characterization of an iron-regulated hemin-binding protein, HbpA, from Leptospira interrogans serovar Lai. Infect Immun (2007) 1.04
Schistosome N-glycans containing core alpha 3-fucose and core beta 2-xylose epitopes are strong inducers of Th2 responses in mice. Eur J Immunol (2003) 1.04
Effect of increased expression of protein disulfide isomerase and heavy chain binding protein on antibody secretion in a recombinant CHO cell line. Biotechnol Prog (2005) 1.03
Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB J (2002) 1.03
Knockout of an endogenous mannosyltransferase increases the homogeneity of glycoproteins produced in Pichia pastoris. Sci Rep (2013) 1.02
Arabidopsis thaliana beta1,2-xylosyltransferase: an unusual glycosyltransferase with the potential to act at multiple stages of the plant N-glycosylation pathway. Biochem J (2005) 1.02
The response to unfolded protein is involved in osmotolerance of Pichia pastoris. BMC Genomics (2010) 1.02
Next-generation sequencing of the Chinese hamster ovary microRNA transcriptome: Identification, annotation and profiling of microRNAs as targets for cellular engineering. J Biotechnol (2011) 1.01
Production of complex multiantennary N-glycans in Nicotiana benthamiana plants. Plant Physiol (2011) 1.01
Specificity of IgG and IgE antibodies against plant and insect glycoprotein glycans determined with artificial glycoforms of human transferrin. Glycobiology (2004) 1.01
Rhamnogalacturonan II structure shows variation in the side chains monosaccharide composition and methylation status within and across different plant species. Plant J (2013) 1.00
Two novel types of O-glycans on the mugwort pollen allergen Art v 1 and their role in antibody binding. J Biol Chem (2004) 0.99
Engineering of sialylated mucin-type O-glycosylation in plants. J Biol Chem (2012) 0.99
Characterizing the link between glycosylation state and enzymatic activity of the endo-β1,4-glucanase KORRIGAN1 from Arabidopsis thaliana. J Biol Chem (2013) 0.99
Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost (2006) 0.99
The N-glycans of yellow jacket venom hyaluronidases and the protein sequence of its major isoform in Vespula vulgaris. FEBS J (2005) 0.99
Arabidopsis thaliana alpha1,2-glucosyltransferase (ALG10) is required for efficient N-glycosylation and leaf growth. Plant J (2011) 0.99